Randomized Open-Label Phase 2 Study of Low Dose DACOGEN (Decitabine) for Injection in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.

Trial Profile

Randomized Open-Label Phase 2 Study of Low Dose DACOGEN (Decitabine) for Injection in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2013

At a glance

  • Drugs Decitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2013 Results published in the Journal of Clinical Oncology.
    • 28 Feb 2013 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
    • 01 Mar 2012 Primary endpoint 'Clinical-improvement-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top